4/A: CVS Health Executive J. David Joyner Amends Filing to Clarify Stock Option and Appreciation Right Grants

J. David Joyner, President and CEO of CVS Health, amends a previous SEC filing to clarify the details of stock options and stock appreciation rights granted to him.

Summary

• J. David Joyner, President and CEO of CVS Health, filed an amendment to a previous Form 4 filing with the SEC.
• The amendment clarifies details regarding a stock option to acquire 1,000,000 shares of CVS Health common stock and a stock-settled stock appreciation right (SAR) with respect to 492,537 shares of CVS Health common stock.
• Both the option and the SAR have a premium exercise or grant price of $71.82.
• The option and SAR become exercisable in three equal annual installments, starting November 30, 2025.
• The amendment confirms that there was no change to the aggregate grant date value of the award as reflected in the original filing.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. The clarification of the stock option and SAR grants is a neutral event.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but it does outline the vesting schedule for the stock options and SARs granted to the reporting person.

Management Comments

• The Issuer made certain administrative modifications to the Reporting Person's November 30, 2024 grant agreement, confirming that the Reporting Person was granted a stock option to acquire 1,000,000 shares of Issuer common stock and a stock-settled stock appreciation right ('SAR') with respect to 492,537 shares of Issuer common stock, each at a premium exercise or grant price, as applicable, of $71.82.

Industry Context

Executive compensation packages, including stock options and SARs, are common in the healthcare industry to incentivize performance and align executive interests with shareholder value. The specifics of these packages vary based on company size, performance, and industry benchmarks.

Comparison to Industry Standards

• Executive compensation packages, including stock options and SARs, are common in large, publicly traded companies like CVS Health.
• Companies like UnitedHealth Group (UNH) and Cigna (CI) also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry standards, aiming to retain and motivate key personnel over the long term.

Stakeholder Impact

• Shareholders may be interested in the details of executive compensation packages as they relate to company performance and alignment of interests.
• Employees may be interested in the details of executive compensation packages as they relate to company performance and alignment of interests.

Key Dates